▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1346 by analyst upside · 2026-09-28
PTCT
PTC Therapeutics, Inc.
Healthcare · Market Cap $5B · P/E 0x
ANALYST PRICE TARGET
+62.4%
implied upside to consensus target
Current Price $62.67
Consensus Target $101.79
Bull Target $137.0
Bear Target $70.0
Analysts Covering 14
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
8
Hold
1
Sell
1
52-Week Low $58.9
52-Week High $90.87
YTD Return -18.3%
FUNDAMENTALS
Market Cap $5B
P/E Ratio (TTM) N/A
Forward P/E 23.4x
EPS (TTM) $-0.67
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $1.0B
Profit Margin -3.8%
52-WEEK RANGE
52-Week Low $58.9
52-Week High $90.87
Current Price $62.67
Bear Target $70.0
Bull Target $137.0
● Now $62.67 ● Target $101.79
TRADING DATA
Avg Volume 1.4M
YTD Return -18.3%
Analyst Count 14
Consensus Buy
Upside to Target +62.4%
Last Updated 2026-09-28

ANALYST SUMMARY

PTC Therapeutics, Inc. (PTCT) is currently trading at $62.67 with a Wall Street consensus price target of $101.79, implying potential upside of 62.4% over the next 12 months. 14 analysts currently cover PTCT, with a consensus rating of Buy - 86% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $137.0, while the most cautious has a target of $70.0.

PTCT operates in the Healthcare sector with a market capitalisation of $5B. The stock is down 18.3% year-to-date and is currently trading near the lower end of its 52-week range of $58.9 – $90.87.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

GRFS +47.8%
Grifols, S.A.
$5B · P/E 9.8x · Buy
INDV +36.8%
Indivior Pharmaceuticals, Inc.
$4B · P/E 12.8x · Buy
ACAD +55.5%
Acadia Pharmaceuticals Inc.
$4B · P/E 9.3x · Buy
PACS +42.9%
PACS Group, Inc.
$7B · P/E 24.2x · Buy
CON +17.1%
Concentra Group Holdings Parent, Inc.
$4B · P/E 22.6x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for PTCT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Cantor Fitzgerald - Reiterated
Overweight → Overweight 2026-09-22 40% win rate (10 calls)
Barclays - Reiterated
Overweight → Overweight 2026-08-14 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2026-08-13 Building track record
Morgan Stanley - Reiterated
Overweight → Overweight 2026-07-31 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2026-07-31 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2026-07-20 Building track record
Cantor Fitzgerald - Reiterated
Overweight → Overweight 2026-07-16 40% win rate (10 calls)
RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-07-07 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
52
out of 100
Coverage depth
21/30
Consensus clarity
9/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →